StoneX Maintains Speculative Buy on Intensity Therapeutics, Lowers Price Target to $8

Benzinga · 2d ago
StoneX analyst Robert Wasserman maintains Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and lowers the price target from $12 to $8.